Comparison of abacavir-specific effector and proliferating functions of CD8 T cells in abacavir-treated HIV-1 patients.
CD8 T cells
HLA-B*57:01
abacavir
hypersensitivity
Journal
Microbiology and immunology
ISSN: 1348-0421
Titre abrégé: Microbiol Immunol
Pays: Australia
ID NLM: 7703966
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
31
07
2019
revised:
28
11
2019
accepted:
16
12
2019
pubmed:
27
12
2019
medline:
19
8
2020
entrez:
27
12
2019
Statut:
ppublish
Résumé
Susceptibility to abacavir hypersensitivity (ABH) in HIV-1-positive patients is strongly linked to the carriage of HLA-B*57:01 and the potential mechanism includes drug-specific activation of cytokine producing CD8 T cells exclusively in individuals carrying HLA-B*57:01. Here, we report a detailed characterization of abacavir-induced functional response of CD8 T cells in HLA-B*57:01
Identifiants
pubmed: 31876322
doi: 10.1111/1348-0421.12769
doi:
Substances chimiques
Anti-HIV Agents
0
Cytokines
0
Dideoxynucleosides
0
HLA-B Antigens
0
HLA-B57 antigen
0
Interferon-gamma
82115-62-6
abacavir
WR2TIP26VS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
210-218Subventions
Organisme : Barb Ibbotson ACHF Chair in Pediatric Hematology Award
ID : #60-28850
Organisme : Calgary Laboratory Services
ID : #1000736
Organisme : Alberta Children Hospital Research Institute
Informations de copyright
© 2019 The Societies and John Wiley & Sons Australia, Ltd.
Références
Cutrell AG, Hernandez JE, Fleming JW, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38(12):2171-2.
Carolino F, Santos N, Piñeiro C, et al. Prevalence of abacavir-associated hypersensitivity syndrome and HLA-B*5701 allele in a Portuguese HIV-positive population. Porto Biomed J. 2017;2(2):59-62.
Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-79.
Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS. 1999;13(8):999-1000.
Berka N, Gill JM, Liacini A, O'Bryan T, Khan FM. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta. Hum Immunol. 2012;73(2):164-7.
Mounzer K, Hsu R, Fusco JS, et al. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study. AIDS Res Ther. 2019;16(1):1.
Schutte RJ, Sun Y, Li D, Zhang F, Ostrov DA. Human leukocyte antigen associations in drug hypersensitivity reactions. Clin Lab Med. 2018;38(4):669-77.
Fan WL, Shiao MS, Hui RC, et al. HLA association with drug-induced adverse reactions. J Immunol Res. 2017;2017:3186328.
Adam J, Pichler WJ, Yerly D. Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol. 2011;71(5):701-7.
Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, McCluskey J. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol. 2012;52:401-31.
Pavlos R, Mallal S, Ostrov D, et al. T cell-mediated hypersensitivity reactions to drugs. Annu Rev Med. 2015;66:439-54.
Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003 21;139(8):683-93
Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2(4):301-5.
Adam J, Eriksson KK, Schnyder B, Fontana S, Pichler WJ, Yerly D. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol. 2012;42(7):1706-16.
Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012;486(7404):554-8.
Llano A, Brander C. Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome. Cell Res. 2012;22(12):1637-9.
Adam J, Wuillemin N, Watkins S, et al. Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses. PLoS One. 2014;9(4):e95339.
Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008;28(6):822-32.
Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA. 2004;101(12):4180-5.
Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23(10):1603-14.
Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J Immunol. 2005;174(5):3051-8.
Phillips EJ, Mallal SA. Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration. J Clin Invest. 2018;128(7):2746-9.
Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19(9):979-81.
Easterbrook PJ, Waters A, Murad S, et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med. 2003;4(4):321-4.
Yun J, Adam J, Yerly D, Pichler WJ. Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy. 2012;67(11):1338-46.
Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS. 2012;26(11):F21-9.
Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol. 2007;81(16):8468-76.
Khan F, Sy S, Liu S, et al. Each herpesvirus elicits a unique T cell response in chronically infected, healthy individuals [Abstract]. Clin Immunol. 2009;131(Suppl,):s64.
Macdonald WA, Purcell AW, Mifsud NA, et al. A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J Exp Med. 2003;1985):679-91.
Mifsud NA, Purcell AW, Chen W, Holdsworth R, Tait BD, McCluskey J. Immunodominance hierarchies and gender bias in direct T(CD8)-cell alloreactivity. Am J Transplant. 2008;8(1):121-32.
Lucas A, Lucas M, Strhyn A, et al. Abacavir-reactive memory T cells are present in drug naïve individuals. PLoS One. 2015;10(2):e0117160.
Almeida CA, van Miert P, O'Driscoll K, et al. Virus-specific T-cell clonotypes might contribute to drug hypersensitivity reactions through heterologous immunity. J Allergy Clin Immunol. 2019;144(2):608-11.